Hawkes CP, Gunturi H, Dauber A, et al. - Researchers examined if disparities in growth hormone (GH) stimulation testing and/or prescribing patterns in children referred for endocrine evaluation of short stature are responsible for the racial/ethnic inequity in GH use. Performing retrospective chart review, they included 7,425 children [aged 2-16 years; height z-score ≤ –1.5; 5,905 non-Hispanic White (NHW), 800 non-Hispanic Black (NHB), or 720 Hispanic race/ethnicity] referred for endocrine growth evaluation between January 2012 and December 2019. A total of 992 children received GH stimulation testing, and 576 were prescribed GH. Observations revealed the existence of racial and ethnic disparities in the evaluation and treatment of children with disordered growth. Both over investigation of NHW children, as well as under investigation and undertreatment of children from minority communities, resulted in these disparities. Clinical concern alone should determine the evaluation and treatment of children with short stature, but this is not current practice.